AVANIR Pharmaceuticals (FRA:AV2B) LT-Debt-to-Total-Asset : 0.00 (As of Sep. 2014)

View and export this data going back to . Start your Free Trial

What is AVANIR Pharmaceuticals LT-Debt-to-Total-Asset?

LT Debt to Total Assets is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. It is calculated as a company's Long-Term Debt & Capital Lease Obligationdivide by its Total Assets. AVANIR Pharmaceuticals's long-term debt to total assests ratio for the quarter that ended in Sep. 2014 was 0.00.

AVANIR Pharmaceuticals's long-term debt to total assets ratio declined from Sep. 2013 (0.28) to Sep. 2014 (0.00). It may suggest that AVANIR Pharmaceuticals is progressively becoming less dependent on debt to grow their business.

AVANIR Pharmaceuticals LT-Debt-to-Total-Asset Historical Data

The historical data trend for AVANIR Pharmaceuticals's LT-Debt-to-Total-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AVANIR Pharmaceuticals LT-Debt-to-Total-Asset Chart

AVANIR Pharmaceuticals Annual Data

Trend

Sep05

Sep06

Sep07

Sep08

Sep09

Sep10

Sep11

Sep12

Sep13

Sep14

LT-Debt-to-Total-Asset

Get a 7-Day Free Trial

0.31

0.28

AVANIR Pharmaceuticals Quarterly Data
	Dec09	Mar10	Jun10	Sep10	Dec10	Mar11	Jun11	Sep11	Dec11	Mar12	Jun12	Sep12	Dec12	Mar13	Jun13	Sep13	Dec13	Mar14	Jun14	Sep14
LT-Debt-to-Total-Asset	Get a 7-Day Free Trial															0.28	0.30	0.19	0.11	-

AVANIR Pharmaceuticals LT-Debt-to-Total-Asset Calculation

AVANIR Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the fiscal year that ended in Sep. 2014 is calculated as

LT Debt to Total Assets (A: Sep. 2014 )	=	Long-Term Debt & Capital Lease Obligation (A: Sep. 2014 )	/	Total Assets (A: Sep. 2014 )
	=	0	/	238.219
	=	0.00

AVANIR Pharmaceuticals's Long-Term Debt to Total Asset Ratio for the quarter that ended in Sep. 2014 is calculated as

LT Debt to Total Assets (Q: Sep. 2014 )	=	Long-Term Debt & Capital Lease Obligation (Q: Sep. 2014 )	/	Total Assets (Q: Sep. 2014 )
	=	0	/	238.219
	=	0.00

AVANIR Pharmaceuticals (FRA:AV2B) LT-Debt-to-Total-Asset Explanation

LT Debt to Total Asset is a measurement representing the percentage of a corporation's assets that are financed with loans and financial obligations lasting more than one year. The ratio provides a general measure of the financial position of a company, including its ability to meet financial requirements for outstanding loans. A year-over-year decrease in this metric would suggest the company is progressively becoming less dependent on debt to grow their business.

AVANIR Pharmaceuticals LT-Debt-to-Total-Asset Related Terms

Thank you for viewing the detailed overview of AVANIR Pharmaceuticals's LT-Debt-to-Total-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

AVANIR Pharmaceuticals (FRA:AV2B) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » AVANIR Pharmaceuticals (FRA:AV2B) » Definitions » LT-Debt-to-Total-Asset

Traded in Other Exchanges

N/A

Address

Website

http://www.avanir.com

Avanir Pharmaceuticals was incorporated in California in August 1988 and was reincorporated in Delaware in March 2009. The Company is a biopharmaceutical company focused on acquiring, developing and commercializing novel therapeutic products for the treatment of central nervous system disorders. The Company commenced promotion of NUEDEXTA in the United States in February 2011. The Company is also studying AVP-923 for use in different types of neuropathic pain. NUEDEXTA is the first and only FDA-approved treatment for pseudobulbar affect. NUEDEXTA is an combination of two components: dextromethorphan hydrobromide, the ingredient that is harmacologically active in the central nervous system, and quinidine sulfate, a metabolic inhibitor enabling dextromethorphan to reach therapeutic plasma concentrations. The Company currently markets NUEDEXTA to approximately 10,000 physicians and other healthcare providers who specialize in psychiatry, neurology or geriatric medicine and practice in outpatient or long-term care settings. NUEDEXTA may face competition from several products: Antidepressants, including Prozac, Celexa, Zoloft, Paxil, Elavil and Pamelor and others; Atypical antipsychotic agents, including Zyprexa, Risperdal, Seroquel, Abilify, Geodon and others; and Miscellaneous agents, including Symmetrel, Lithium and others. The Company is subject to regulation under the Occupational Safety and Health Act, the Environmental Protection Act, the Toxic Substance Control Act, the Export Control Act and other present and future laws of general application.

AVANIR Pharmaceuticals (FRA:AV2B) Headlines

No Headlines